Angel Qin, MD
Clinical Associate Professor of Internal Medicine
Medical School
Michigan Medicine
Internal Medicine - Hematology/Oncology
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Internal Medicine - Hematology/Oncology
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Available to mentor
Angel Qin, MD
Clinical Associate Professor
Manage Your Profile
About
I am a medical oncologist who takes care of patients with lung cancers and other thoracic cancers. I am interested in clinical trials looking at new drugs or combinations. My research interests are in mechanisms of resistance to treatment.
Center Memberships
-
Center MemberRogel Cancer Center
Recent Publications
-
Qin A. 2026 Jun 2;PresentationRaising the Bar in ALK and RET
-
Fortman D, Savitch S, Lagisetty K, Qin A. Journal of Thoracic Oncology, 2026 May 9; 21 (5): 103838Journal ArticlePP01.101: Real-World Evaluation of Biomarkers Predicting Response to Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
DOI:10.1016/j.jtho.2026.103838 -
Schoenfeld A, Spira A, Lisberg AE, Gutierrez ME, Sankhala K, Byrne M, Reckamp KL, Qin A, Marron TU, Konduri K, Richards DA, Paschold J, Layman C, Schenk EL, Parikh K, Lou Y, Ernani V, Adjei A, Altan M, Qiu Y, Fang H, Mu H, Pinho M, Reed T, Soland M, Tibes R, Türeci Ö, Sahin U, Paz-Ares L. Journal of Thoracic Oncology, 2026 May 9; 21 (5): 103852Journal ArticlePP01.118: Phase 1b/2 trial of BNT324/DB-1311 (B7H3 ADC) with Pumitamig (BNT327; PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC): BNT324-01 Trial in Progress
DOI:10.1016/j.jtho.2026.103852 -
Patil T, Watson A, Martin AC, Wise HK, Schmitt E, Reventaite E, Filar E, Miller E, Yoder BA, Schenk EL, Qin A. Journal of Thoracic Oncology, 2026 May 9; 21 (5): 103767Journal ArticlePP01.24: Interim Safety and Efficacy of a Phase 1/2, Open-Label Study of Amivantamab in Combination With Tyrosine Kinase Inhibitors Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions
DOI:10.1016/j.jtho.2026.103767 -
Chen Y, Fouladdel S, Kidder L, Tang Y, Ball H, Serhan H, Qin Z, Liu A, Cheng X, Bao L, Kathawate V, Goo L, Horn M, Fry S, Hata AN, Gainor J, Lin JJ, Hinton S, Huang CH, Merrill N, Udager AM, Ulintz PJ, Qin A, Merajver S, Nagrath S. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 1062 - 1062.Journal ArticleAbstract 1062: Longitudinal monitoring of circulating tumor cells (CTC) reveals dynamic CTC behaviors associated with disease progression and survival in ALK-positive NSCLC
DOI:10.1158/1538-7445.am2026-1062 -
Raghavan R, Apfel A, Serhan H, Qin A, Liu C-J, Nakhjiri M, Merajver SD, Udager A, Merrill N. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 1766 - 1766.Journal ArticleAbstract 1766: Dual EGFR and Bcl-2 inhibition overcomes resistance in sinonasal squamous cell carcinoma
DOI:10.1158/1538-7445.am2026-1766 -
Banerjee A, Busette N, Cheng X, Kohagen K, Bao L, Lopez-Barcons L, Berger MS, Soellner MB, Qin A, Merajver S, Merrill N. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 469 - 469.Journal ArticleAbstract 469: Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies.
DOI:10.1158/1538-7445.am2026-469 -
Madhi H, Serhan H, Mercer R, Levy B, Rottinghaus A, Bao L, Cheng X, Pine SR, Camidge R, Qin A, Merrill NM, Merajver SD, Soellner MB. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 6501 - 6501.Journal ArticleAbstract 6501: Preclinical evidence for synergistic activity of alectinib and everolimus in ALK-positive non-small cell lung cancer
DOI:10.1158/1538-7445.am2026-6501
Featured News & Stories
Department News
CME Event - Advances in the Treatment of Stage III Non-Small Cell Lung Cancer
The Advances in the Treatment of Stage III Non-Small Cell Lung Cancer (NSCLC) CME webinar, featuring a panel discussion with Michigan Medicine faculty from hematology and oncology, radiation oncology, pulmonary and critical care medicine, and thoracic surgery, will provide an update on the evolving landscape of NSCLC treatment.
